Research institution
Assistance Publique - Hôpitaux de Paris Clinical Trials
Studies where Assistance Publique - Hôpitaux de Paris is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 884Hyponatremia
Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.
- Trial name
- DASSOH (NCT06020495)
- Testing
- DDAVP, Standard hyponatremia treatment
- Where
- 15 sites in France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cerebrovascular Disorders
Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.
- Trial name
- LEOPOLD (NCT02472028)
- Testing
- blood pressure lowering algorithm, usual strategy
- Where
- 2 sites in France
- Volunteers
- 820 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffusion Tensor Imaging Prognosis, Brain Injury, Traumatic
Description of Clinicians' Predictive Abilities Before and After a Diffusion Tensor Imaging (DTI)
With a mortality rate of over 13% in the neuro-intensive care unit, 86% of which are related to the withdrawal of active treatment, predicting a reliable neurological prognosis is of paramount importance in neuro-intensive care…
- Trial name
- Neuro-FORECAST (NCT07863414)
- Testing
- Questionnaire
- Where
- 8 sites in France
- Volunteers
- 220 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure
Virtual Human Twins as Tools for Personalized Clinical Care in Heart Failure With Preserved Ejection Fraction: a Pilot Study
Heart failure (HF) is a heterogeneous clinical syndrome characterized by substantial inter-individual variability in pathophysiology and response to treatment.
- Trial name
- VITAL-HF (NCT07902453)
- Testing
- Data collection for the development and validation of the cardiovascular virtual human twin
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Septic Shock
Comparison of Cardiac Index Measurement Using Right Ventricular Pressure Curve Analysis and Thermodilution Via a Swan-Ganz IQ™ Catheter.
The pulmonary artery catheter (Swan-Ganz) is a standard tool in intensive care for measuring and monitoring cardiac index by thermodilution.
- Trial name
- MICAP (NCT07628023)
- Testing
- Swan-Ganz
- Where
- 2 sites in France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Heart Failure (AHF)
Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
Acute heart failure (AHF) is a major cause of acute dyspnea in emergency departments (EDs), driven primarily by venous congestion, which can lead to hepatic congestion and risk of subsequent liver dysfunction.
- Trial name
- FIBROSCAF (NCT07449377)
- Testing
- FibroScan®
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ehlers-Danlos Syndromes (EDS)
CLINICAL AND BIOLOGICAL DATABASE OF PATIENTS WITH NON-VASCULAR EHLERS-DANLOS SYNDROMES
The Rare Disease Reference Center (CRMR) for Non-Vascular Ehlers-Danlos Syndromes (NV-EDS) at the Raymond Poincaré University Hospital provides diagnosis and care for patients with non-vascular Ehlers-Danlos syndrome.
- Trial name
- BASE SED-NV (NCT07899489)
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ehlers-Danlos Syndromes (EDS)
Evaluation of the Role of Serum Tenascin-X Levels in the Diagnosis of Hypermobile Ehlers-Danlos Syndrome
Thirteen types of EDS have been described based on their clinical manifestations and genetic backgrounds. Their diagnosis relies on personal and family medical history, together with established clinical criteria.
- Trial name
- DIAGNOSEDh (NCT07899554)
- Testing
- Blood sampling
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Transplantation
Superiority Assessment of Donor-derived Cell-FreE DNA ( Deoxyribonucleic Acid) for Cardiac Allograft REjection Monitoring
Heart transplantation (HTx) remains the gold-standard treatment for patients with end-stage heart failure refractory to the medical management, offering the best survival and quality of life.
- Trial name
- SAFE-CARE (NCT07897526)
- Testing
- non-invasive strategy based of the analysis of circulating dd-cfDNA (AlloSeq cfDNA assay), control
- Volunteers
- 352 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Children <24 Months Hospitalized for RSV-related Lower Respiratory Tract Infection
Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis
Hospitalization for RSV lower respiratory tract infections (LRTI) still occurs, including in infants having received nirsevimab/clesrovimab or born to mothers vaccinated with Abrysvo.
- Trial name
- SiRiUS (NCT07893652)
- Testing
- Prior exposure to prophylactic treatment with Abrysvo or nirsevimab/clesrovimab, Non-exposure to prior prophylactic treatment
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Completed, with results posted
All 7Cardiac Arrest, Sudden Death
A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (APACAR2)
Cardiac arrest (CA) affects approximately 40,000 people in France. It is still a major cause of death in a young population. Management of CA is defined by international recommendations, detailed by learned societies in each…
- Trial name
- APACAR2 (NCT02527031)
- Testing
- ECMO Insertion on pre hospital setting, In Hospital ECMO
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Corona Virus Infection
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).
- Trial name
- CORIMUNO-TOC (NCT04331808)
- Testing
- Tocilizumab
- Where
- 8 sites in France
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Corona Virus Infection
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).
- Trial name
- CORIMUNO-SARI (NCT04324073)
- Testing
- Sarilumab
- Where
- 4 sites in France
- Volunteers
- 239 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Corona Virus Infection
CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection
The overall objective of the study is to determine the therapeutic effect and tolerance of Anakinra in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).
- Trial name
- CORIMUNO-ANA (NCT04341584)
- Testing
- Anakinra
- Where
- France
- Volunteers
- 161 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systematic Review
Impact of Adding a Limitation Section in Abstract of Systematic Review
Objective: The investigators aim to evaluate the impact of a adding a " limitations " section in systematic review's abstract on result's interpretation by readers Design: randomized controlled trial with two parallel arms.
- Trial name
- ILMARI2 (NCT01848782)
- Testing
- interpretation of the abstract of the systematic review
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris